Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

17 Feb 2021

Mindset Pharma Announces U.S. Listing Application for OTCQB Venture Market

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

17 Feb 2021

Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode

Vancouver, BC – Havn Life Sciences Inc....

By Microdose

Press Releases

16 Feb 2021

Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results

Q3 2021 patient services revenues of $316,329 represent a 235% increase over the previous quarter Field Trip continues to advance development of FT-104, a novel psychedelic molecule with pending patents...

By Microdose

Press Releases

16 Feb 2021

REPEAT — Pure Extracts Agrees to Licensing deal with Taste-T, LLC the US manufacturer of Fireball Cannabis Gummies

VANCOUVER, British Columbia, Feb....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

16 Feb 2021

Cybin Inc. Releases Financial Highlights and Provides Business Update

Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines Adelia Therapeutics...

By Microdose

Press Releases

16 Feb 2021

Pure Extracts Agrees to Licensing deal with Taste-T, LLC the US manufacturer of Fireball Cannabis Gummies

VANCOUVER, British Columbia, Feb....

By Microdose

Press Releases

16 Feb 2021

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

La Jolla, California–(Newsfile Corp....

By Microdose

Press Releases

12 Feb 2021

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

TORONTO, Feb....

By Microdose

Press Releases

12 Feb 2021

The Conscious Acquisition Company Announces the 
First Psychedelic Medicine Focused SPACs

Exchange Listing, LLC and The Conscious Fund announce their partnership and the creation of The Conscious Acquisition Company....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.